<DOC>
	<DOCNO>NCT02284828</DOCNO>
	<brief_summary>Single-blind , single-centre , fixed-order study evaluate PD effect single oral dose multiple oral dos ESL ( BIA 2-093 ) healthy volunteer .</brief_summary>
	<brief_title>Effects Eslicarbazepine Acetate ( BIA 2-093 ) Cognition Psychomotor Function</brief_title>
	<detailed_description>Single-blind , single-centre , fixed-order study evaluate PD effect single oral dose multiple oral dos ESL ( BIA 2-093 ) healthy volunteer . A single dose oral ESL 900 mg follow consecutive 7-day period : Placebo , ESL 800 mg , ESL 1200 mg give QD . The single dose choose assess ESL acute response relationship respect cognitive motor skill performance , multiple dos choose characterize ESL dose response relationship respect cognitive motor skill performance .</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Healthy male female subject , 18 45 year age , inclusive Having complete least high school level education ( base personal report ) Native speaker English language learn English 12 year age Understood provide write informed consent prior initiation protocolspecific procedure Body mass index ( BMI ) within range 18 30 kg/m2 , inclusive , minimum weight least 50 kg Free clinically significant abnormality basis medical history , vital sign , physical examination , 12lead ECG , laboratory evaluation Screening . Female subject childbearing potential practiced abstinence use willing continue use medically acceptable form birth control least 1 month prior Screening least 1 month last study drug administration . Medically acceptable form contraception include intrauterine device doublebarrier . Hormonebased contraceptive method acceptable , ESL may decrease effectiveness . Female subject nonchildbearing potential amenorrheic least 2 year hysterectomy and/or bilateral oophorectomy . Male subject require use doublebarrier form contraception Subjects willing able abide study requirement restriction History presence drug alcohol dependence ( exclude nicotine caffeine ) , include subject ever drug rehabilitation program , base medical history Clinically significant abnormality physical examination , medical history , 12lead ECG , vital sign , laboratory value , judge investigator designee Current psychiatric illness , except nicotine caffeine dependence . Subjects past history psychiatric illness exclude discretion investigator designee History presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic , psychiatric disease condition , opinion investigator could jeopardize safety subject validity study result Use nonprescription drug within 7 day prior first study drug administration . Unless opinion investigator designee , medication receive interfere study procedure data integrity compromise safety subject Use prescription medication natural health product ( except acceptable form birth control hormone replacement ) within 14 day prior first study drug administration throughout study , unless opinion investigator designee , product interfere study procedure data integrity compromise safety subject Positive serum pregnancy screen follow Screening positive urine pregnancy screen admission Days −1 , 9 , 16 Positive urine drug screen ( 5panel MedTox kit ) Screening , Day −1 , Day 9 , Day 16 . Positive breath alcohol test Screening , Days −1 , 9 , 16 Female subject pregnant lactate plan become pregnant within 60 day last study drug administration History allergy hypersensitivity ESL , related drug , drug excipients drug product component Positive Hepatitis B , Hepatitis C , HIV Current pending legal charge Treatment investigational drug within 30 day prior first drug administration A subject , opinion investigator designee , consider suitable unlikely comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>